Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Tag archive for ‘Celldex Therapeutics Inc.’

Comments on Agenus, Neuralstem and Celldex

SmithOnStocks Mailbox About the Mailbox: My mailbox comments are brief articles on stocks in which I am involved. These can come from recent events or from subscribers’ questions. They are meant to address specific issues about these stocks and are not full and balanced reports. Please refer to the Reports section of my website for […]

Thoughts on the Market Correction in Biotechnology Stocks

This Has Been a Tough Correction The recent sharp market correction and rotation out of growth stocks like biotechnology and technology has had a major impact on the small biotechnology names that I specialize in. The correction has been stomach churning for me even though I have been through this many times before. I am […]

Celldex (CLDX, $23.06): Previewing the Imminent Data Release on Rindopepimut

Note: Comprehensive reports are now available to paid subscribers and can be found in the Reports section. Investment Background and Thesis This post is the summary of a much more extensive report that is available to paid subscribers. In that report, I discuss rindopepimut and other cancer vaccines for GBM in more detail. In my initial report on […]

Celldex (CLDX, $23.06): Previewing the Imminent Data Release on Rindopepimut

Investment Background and Thesis In my initial report on Celldex, I highlighted four interesting products that the Company has in development. Two of these are in randomized phase II or III trials that could be the basis for regulatory filings: rindopepimut for glioblastoma (GBM) and CDX-011 or glembatumab for triple negative GPNMB positive breast cancer. I […]